What You Need to Know About Getting Your Weight-Loss Medication

Who Qualifies for a Prescription Weight-Loss Medication

The FDA has approved specific body-mass-index thresholds for chronic weight-management drugs. You qualify if your BMI is 30 kg/m² or above, or if your BMI is 27 kg/m² or above and you have at least one weight-related comorbidity. Recognized comorbidities include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease.

These thresholds mirror the 2013 AHA/ACC/TOS guideline on the management of overweight and obesity in adults, which recommended pharmacotherapy as an adjunct to lifestyle intervention when diet and exercise alone produce insufficient results [1]. The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity reinforced this framework, specifying that drug therapy should be considered only when behavioral modifications have not achieved a clinically meaningful weight loss of at least 5% over three to six months [2].

In practice, a prescribing clinician will review your full medical history before writing a prescription. They assess blood pressure, fasting glucose, lipid panel, liver function, kidney function, and any history of pancreatitis or thyroid tumors, because several GLP-1 agents carry a boxed warning for thyroid C-cell tumors in rodent studies [3]. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are excluded from semaglutide and tirzepatide.

Age also matters. All currently approved agents are labeled for adults aged 18 and older. Wegovy received an additional approval in December 2022 for adolescents aged 12 and older with obesity [4].

The Medications Currently Available and What They Do

Five drug regimens currently hold FDA approval specifically for chronic weight management in adults without diabetes. Each works through a different mechanism, carries a different efficacy profile, and suits a different patient.

Orlistat (Xenical, Alli) blocks pancreatic lipase, reducing dietary fat absorption by roughly 30%. In a 52-week randomized trial, orlistat 120 mg three times daily produced a mean weight loss of 8.9 kg versus 5.8 kg with placebo [5]. The gastrointestinal side-effect burden (oily spotting, fecal urgency) limits adherence.

Phentermine-topiramate extended-release (Qsymia) combines a sympathomimetic amine with an anticonvulsant. The EQUIP trial (N=1,267) showed the highest dose (15 mg/92 mg) produced a 10.9% placebo-adjusted weight loss at 56 weeks [6]. Teratogenicity requires a Risk Evaluation and Mitigation Strategy (REMS) program for women of childbearing potential [7].

Naltrexone-bupropion extended-release (Contrave) acts on the hypothalamic melanocortin system and the mesolimbic reward pathway. The COR-I trial (N=1,742) demonstrated 6.1% placebo-adjusted weight loss at 56 weeks [8].

Semaglutide 2.4 mg subcutaneous weekly (Wegovy) is a GLP-1 receptor agonist that slows gastric emptying and suppresses appetite through central and peripheral mechanisms. STEP-1 (N=1,961) showed 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [9]. The SELECT cardiovascular outcomes trial (N=17,604) subsequently demonstrated a 20% reduction in major adverse cardiovascular events in adults with established cardiovascular disease and obesity, leading to an expanded FDA indication in March 2024 [10].

Tirzepatide 15 mg subcutaneous weekly (Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. SURMOUNT-1 (N=2,539) demonstrated up to 22.5% mean body weight loss at 72 weeks with the 15 mg dose versus 2.4% placebo (P<0.001) [11]. That is the largest mean weight reduction recorded in a phase 3 pharmacotherapy trial for obesity to date.

A simplified selection framework used by the HealthRX medical team places patients into three tiers based on efficacy need, comorbidity profile, and cost tolerance. Tier 1 (BMI 27, 30, no cardiovascular disease, cost-sensitive) starts with orlistat or phentermine-topiramate. Tier 2 (BMI 30, 35, metabolic comorbidities, moderate cost tolerance) moves to naltrexone-bupropion or semaglutide 1.0 mg (off-label). Tier 3 (BMI 35 or higher, or established cardiovascular disease, or prior failure on tier 1, 2 agents) prioritizes semaglutide 2.4 mg or tirzepatide as first-choice agents.

How to Get a Prescription: In-Person vs. Telehealth

You have two main pathways. Both require a licensed clinician to evaluate you before prescribing.

Traditional in-person care involves your primary care physician, an endocrinologist, or a bariatric medicine specialist. A comprehensive visit typically includes a physical exam, metabolic labs, and a discussion of lifestyle interventions. The American Academy of Family Physicians supports the use of pharmacotherapy for obesity as part of a broader management plan that includes dietary counseling [12].

Telehealth prescribing has expanded access significantly since 2020. The DEA's 2023 proposed rules on telemedicine prescribing would have required an in-person visit before controlled substances could be prescribed remotely, but phentermine is a schedule IV drug and is subject to those rules. Semaglutide and tirzepatide are not controlled substances, so they may be prescribed via a synchronous video or asynchronous questionnaire visit in most states, depending on state medical board rules [13].

When you contact a telehealth provider, expect to provide your height, weight, current medications, past medical history, and any previous weight-loss attempts. A clinician reviews this information and either approves a prescription or requests labs before proceeding. The FDA does not require a specific lab panel before prescribing GLP-1 agents, but most evidence-based protocols order at minimum a hemoglobin A1c, a comprehensive metabolic panel, and a lipid panel [14].

Prescriptions for semaglutide and tirzepatide are sent to a specialty or compounding pharmacy. Brand-name medications from the manufacturer's own pharmacy network (NovoCare for Wegovy, Lilly's Direct for Zepbound) may be paired with manufacturer savings cards that reduce out-of-pocket cost to as low as $25/month for commercially insured patients [15].

Dosing, Titration, and What the First Three Months Look Like

All GLP-1 and dual GIP/GLP-1 agents use a gradual dose-escalation schedule to reduce nausea and gastrointestinal side effects. Rushing the titration is the most common clinical error.

Semaglutide 2.4 mg (Wegovy) starts at 0.25 mg once weekly for four weeks, then advances through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose at week 17. Patients who cannot tolerate an escalation step stay at the prior dose for an additional four weeks before retrying [16].

Tirzepatide (Zepbound) starts at 2.5 mg once weekly for four weeks, then advances in 2.5 mg increments every four weeks to a target of 5 mg, 10 mg, or 15 mg depending on response and tolerability. Most patients in SURMOUNT-1 reached 10 mg or 15 mg by week 20 [11].

During the first three months, weight loss is often modest. A meta-analysis of GLP-1 receptor agonist trials published in JAMA found that meaningful weight reduction typically becomes clinically evident between weeks 8 and 16 [17]. Nausea is the most reported side effect, occurring in approximately 44% of semaglutide-treated patients in STEP-1 versus 16% with placebo [9]. Eating smaller portions, avoiding high-fat meals, and taking the injection on a consistent day each week can reduce nausea frequency.

Constipation, fatigue, and mild injection-site reactions round out the common adverse events. Serious adverse events including acute pancreatitis, gallbladder disease, and heart rate elevation require prompt reporting to your prescriber [3].

Insurance Coverage and What You Will Actually Pay

Coverage is inconsistent. Medicare Part D was prohibited from covering weight-loss drugs by statute until the Treat and Reduce Obesity Act introduced legislative pressure. As of early 2025, Medicare coverage for semaglutide 2.4 mg exists only for the cardiovascular indication approved in March 2024, not for weight loss alone [10].

Commercial insurance plans vary. A 2023 survey by the Kaiser Family Foundation found that fewer than half of large employer plans covered GLP-1 agents for obesity. Some plans cover them only with a documented BMI of 30 or above plus one comorbidity, matching the FDA label. Others require a prior authorization showing failure of at least one other pharmacological treatment first [18].

Prior authorization (PA) is the most common barrier. Your prescriber will need to submit clinical notes, lab results, and a letter of medical necessity. A PA denial can be appealed. The appeals process is worth pursuing: a 2022 analysis in Health Affairs found that about 40% of initially denied PA requests for obesity medications were ultimately approved on first appeal [19].

Manufacturer discount programs help commercially insured patients significantly. Novo Nordisk's Wegovy savings card can reduce monthly cost to $0 for eligible patients. Eli Lilly's Zepbound savings card sets a $550 cap per month for self-pay patients. These programs do not apply to patients using federal insurance (Medicare or Medicaid) [15].

Compounded semaglutide was widely available between 2022 and 2025 when FDA-declared shortages were in effect. The FDA removed semaglutide 2.4 mg from the shortage list in February 2025, which means compounding pharmacies are no longer legally permitted to produce copies of Wegovy [20]. Compounded tirzepatide remains a gray area as of mid-2025. Patients should ask their prescriber explicitly whether a compounded product they are being offered comes from a 503A or 503B facility and whether it uses the same salt form as the brand-name product.

Lifestyle Requirements: What Prescribers Expect from You

Medication alone does not constitute treatment. Every FDA approval for chronic weight management specifies use "as an adjunct to a reduced-calorie diet and increased physical activity" [3].

Prescribers who follow evidence-based practice will ask about your dietary patterns and physical activity level before and during treatment. The 2021 American Gastroenterological Association guideline on pharmacological interventions for adults with obesity recommends setting a realistic calorie deficit of 500 to 750 kcal per day in addition to pharmacotherapy [21]. That translates to roughly 1,200, 1,500 kcal/day for most women and 1,500, 1,800 kcal/day for most men, depending on baseline metabolic rate.

Physical activity recommendations from the CDC for adults are at least 150 minutes of moderate-intensity aerobic activity per week [22]. Resistance training at least two days per week is encouraged alongside GLP-1 therapy because these medications can cause lean mass loss alongside fat loss, a pattern documented in the STEP-1 body-composition substudies.

Your prescriber should schedule follow-up visits at weeks 4, 12, and 16 to assess tolerability, adjust dosing, and measure weight change. The Endocrine Society recommends discontinuing pharmacotherapy if a patient has not achieved at least a 5% reduction in baseline body weight after 12 to 16 weeks at the therapeutic dose [2]. A lack of response at that point warrants switching agents rather than continuing ineffective treatment.

Long-Term Use and What Happens If You Stop

Obesity is a chronic disease. The body's hormonal counter-regulation against weight loss (including reductions in leptin, increases in ghrelin, and downregulation of thyroid hormone) persists for years after weight is lost [23]. This biology means that most patients who stop GLP-1 therapy regain a significant portion of lost weight.

STEP-4 (N=803) measured what happens after 20 weeks of semaglutide induction when patients were randomized to either continue semaglutide 2.4 mg or switch to placebo for an additional 48 weeks. Those who continued lost an additional 7.9% of body weight. Those switched to placebo regained 6.9%, erasing the majority of their prior loss [24].

The SURMOUNT-4 trial replicated this pattern with tirzepatide: patients who switched from tirzepatide to placebo after 36 weeks of weight loss regained 14 percentage points of body weight over the subsequent 52 weeks [25].

These data support indefinite use for patients who respond and tolerate the medication. If cost or side effects require discontinuation, a plan for intensive behavioral support and possible bridge therapy (such as naltrexone-bupropion or phentermine-topiramate) should be in place before stopping.

Drug Interactions and Contraindications to Discuss With Your Prescriber

GLP-1 receptor agonists slow gastric emptying, which can affect the absorption of oral medications taken around the same time. Oral contraceptives are a particular concern: manufacturers of semaglutide recommend using a non-oral contraceptive method or adding a barrier method during dose escalation and for four weeks after each dose increase, because peak GLP-1 activity may transiently reduce contraceptive plasma levels [16].

Patients on insulin or sulfonylureas face a risk of hypoglycemia when adding a GLP-1 agent, because both drug classes lower blood glucose. Your prescriber should proactively reduce the sulfonylurea or insulin dose at initiation [14].

Naltrexone-bupropion (Contrave) carries a boxed warning for suicidal thoughts, as bupropion is also an antidepressant. It is contraindicated in patients using monoamine oxidase inhibitors, patients with uncontrolled hypertension, and those with a history of seizure disorder [8].

Phentermine-topiramate is contraindicated in glaucoma and hyperthyroidism, and the topiramate component increases the risk of cognitive slowing and metabolic acidosis [6]. Kidney stones occur in approximately 1.5% of patients on topiramate-containing regimens based on postmarketing surveillance data reported to the FDA [7].

Compounded vs. Brand-Name: What You Need to Know Before You Order

Between 2022 and early 2025, FDA drug shortages permitted 503A compounding pharmacies (those filling individual prescriptions) and 503B outsourcing facilities (those producing larger batches) to prepare semaglutide and tirzepatide copies. With the shortage designation lifted for semaglutide, that legal pathway has closed for most compounders.

The FDA has explicitly stated that compounded drugs are not FDA-approved and have not been demonstrated to be safe, effective, or of equivalent quality to the approved product [20]. Purity and potency testing of compounded GLP-1 products by independent labs has found wide variability, with some samples containing degradation products not present in the original formulation.

Patients should ask any compounding pharmacy for a Certificate of Analysis from an accredited third-party lab showing potency, sterility, and endotoxin levels. If a pharmacy cannot or will not provide that document, that is a signal to seek a different supplier or pursue the brand-name product.

Setting Realistic Expectations: Timelines and Outcomes

Weight loss on pharmacotherapy is real, measurable, and clinically meaningful. It is not as fast as bariatric surgery, and it is not permanent without continued treatment.

At 68 to 72 weeks, patients on semaglutide 2.4 mg lose an average of 14.9% of body weight [9]. Those on tirzepatide 15 mg lose an average of 22.5% [11]. Both figures exceed the 5 to 10% threshold at which clinically significant improvements in blood pressure, HbA1c, triglycerides, and sleep apnea severity are routinely observed [1].

Responders (defined as 5% or more weight loss at 16 weeks) have a high probability of achieving 10 to 15% total weight loss by week 52. Non-responders at 16 weeks should switch agents. Partial responders (2 to 5% at 16 weeks) may benefit from continuing to the full maintenance dose before a final judgment is made.

Start your conversation with a prescriber by bringing your current medication list, your most recent labs if available, and a clear statement of your weight-loss history. That information cuts appointment time, reduces the back-and-forth on prior authorization, and lets the clinician start at the right tier of treatment from the first visit.